For ordinary people, the health of the eyes directly affects labor ability and quality of survival. He's Ophthalmology, which was listed on the GEM of the Shenzhen Stock Exchange today, is a group chain medical institution that provides ophthalmology diagnosis and treatment servi

. During the period, he saw that many patients with ophthalmic diseases lacked eye protection and did not accept timely diagnosis and treatment, and eventually seriously affected the quality of survival. The experience of

referring to He Wei's sense of mission of "science and technology". He decided to abandon a wealthy and comfortable life abroad after graduation, and return to China to establish an ophthalmology hospital, so that the domestic public can also enjoy international ophthalmic technology.

In 1995, after graduation, Dr. He Wei returned to China with three major technologies of cataract ultrasound, vitreous cutting, and underground laser laser, and began a difficult road to entrepreneurship.

He's Ophthalmology has developed for more than 20 years. From a small clinic of only 125 square meters in the original family, it has grown into a medical, teaching, and research. Group chain medical institution.

Company has long been cultivating the Liaoning market for a long time. At present, the business has gradually expanded to key cities and surrounding areas including Beijing, Shanghai, Shenzhen and Chongqing. It is worth mentioning that Dr. He Wei and his founding team are worth mentioning in the process of supporting the development of the hospital with the spirit of entrepreneur spirit and innovative characteristics, which always runs through the humanistic care complex in the process of supporting the development of the hospital with entrepreneur spirit and innovators.

has long -term heart -based Dr. He Wei, who hopes to make the biggest effort for the development of Chinese ophthalmology, which is not just to establish an international high -level ophthalmology hospital.

In 2009, Dr. He Wei founded , Liaoning Medical College, approved by the Ministry of Education, and was committed to cultivating more medical talents for the country.

(Liaoning He's College)

, Dr. He Wei also created Shenyang He's Eye Industry Group to develop high -end eye consumables and eye medicines with international competitiveness to create China's eye industrial base and Featured town.

(Shenyang He's Eye Industry Group)

National funding fund blessing, growth excellent

, Dr. He Wei and his team are based on the three major subjects of He's Ophthalmology, He's Medical College, and He's Eye Industry Group. Ophthalmology related medical, education, scientific research, industry, social welfare and other sectors. Among the

, medical care is the core, which is He's ophthalmology that provides patients with international advanced level medical services. It is the original intention of Dr. He Wei's return to China to start a business, and it is also the listed company itself to discuss today. The controlling shareholder and actual controller of

are the three people including Dr. He Wei and his brother He Xiangdong and his wife Fu Lifang, which holds a total of 63.3%of the company's shares.

Other shareholders holding 5%of the shares holding companies, including advanced manufacturing (9.0%of the shares), Meixin Investment (8.9%of the shares), new pine robot (holding 6.6%), Dongsoft Holdings (holding 6.66.6 %) Hezhiji Technology (6.5%of the shares).

(Source: Company Prospectus)

, advanced manufacturing is a private equity fund with a state -owned background, and its largest shareholder is the Ministry of Finance.

(Advanced Manufacturing Funding Structure, Source: Company Prospectus)

In recent years, domestic demand for ophthalmology services has grown rapidly. The reason behind

is that with the rapid popularization of smart terminals such as computers and mobile phones, and accelerating population aging, the prevalence of various types of eye diseases (such as myopia, dry eyes, cataract , etc.) in my country shows a relatively obvious upward trend. According to statistics,

, according to statistics, my country's ophthalmology hospital's revenue scale in 2019 has reached 32.5 billion yuan, and the average annual compound growth rate (CAGR) in the past 10 years has reached 23.7%.

(Source: Company Prospectus)

is worth mentioning that my country's ophthalmological medical service market not only has a considerable prospect, but also gives private enterprises a great room for participation.

In 2019, there are 890 private ophthalmological hospitals in my country, 55 public ophthalmology hospitals, and private ophthalmology hospitals accounted for 94.2%.

(Source: Company Prospectus)

currently, companies, Elominology and Hima Eye Department, are brands with high popularity in the domestic ophthalmology service industry.

(Source: Company Prospectus)

is comparable to the company disclosed in the prospectus. Jia .

(Source: Company Prospectus)

Company has increased rapidly from 610 million yuan in 2018 to 840 million yuan in 2020.

2021 In the first half of the year, with the control of the new crown epidemic, the delayed demand for patients with ophthalmology during the epidemic was gradually released.

(Source: Oriental Fortune Choice)

needs to be pointed out that the ophthalmological service industry represented by the company is limited from the long -term crown epidemic.

is that most of the ophthalmological medical services demand is just needed, such as cataracts provided by the company, refractive and other ophthalmology surgery.

Even if during the epidemic, these demand will only delay and not disappear. is relatively flexible for patients with ophthalmology for patients with ophthalmology.

In addition, during the epidemic, people have greatly increased their eye strength through Internet classes, office, entertainment, and social intensity, which will also promote the continuous growth of ophthalmic medical services. The profitability of

is also increasing.

gross profit margin has shown a slight upward trend in recent years, with 43.4%in 2020. Compared with the comparable company, its gross profit margin is higher than the average of peers during most periods.

(Source: Company Prospectus)

Company's net profit margin and deduction of non -net profit margins have steadily increased. From

2018-2020, the net profit margin of the mother-in-law increased from 9.1%to 12.0%, and the deduction of non-net profit margin increased from 8.8%to 10.6%. In the first half of the

2021, the company realized net profit and non -net profit of 59 million yuan and 58 million yuan, respectively, and the corresponding net profit margin and non -net profit margin of the mother were 12.7%and 12.5%, respectively.

（数据来源：东方财富Choice）

独特的三级医疗服务模式，实现“1+12”规模效益

推动公司优异成长性的背后，是其基于超过20年实践所探索出的可持续、 Copy three -level eye health medical service model.

At present, the company has 90 chain medical institutions, including 3 third -level eye health service institutions, 32 second -level eye health service agencies, and 55 primary eye health care service institutions.

different levels of medical service institutions have clear functions. The primary, secondary, and third levels are positioned as prevention and rehabilitation, common eye disease diagnosis and treatment, and regional difficulty of eye disease diagnosis and treatment.

(three -level eye health care service model, source: company prospectus)

, the top three are all three -level eye health service agencies, which contribute more than 70 % of revenue and profits.

(Source: Company Prospectus)

needs to be pointed out that the company's large number of two and third -level eye health service agencies, although the value of the store is relatively low in the long run, it is for the company's development. It has important strategic significance.

is a second -level eye health service institution that focuses on the optical test store and the outpatient clinic of the operating room, and the second -level eye health service institution that can carry out common eye disease surgery services. It is an important part of the company's medical service network and forms a company. A complete eye health service system. At the same time,

, opening low -level eye health service agencies also means lower investment in the early stage. is conducive to the company's rapid layout and seize market share.

through a reasonable layout of stores, eye health service agencies at all levels are empowering and dependent on each other to achieve the " two -way referral , up and down patients, convenient patients", and finally achieved the operating effect of "1+12".

Company publicly issued 490 million yuan in funding. The fund plan is mainly used to expand the original hospital and open a new hospital.

From the disclosed fundraising project, the company will continue to expand to the Beijing -Tianjin -Hebei region centered on Beijing and the western region centered on Chongqing.

(Source: Company Prospectus)

In Fengyunjun, the company has accumulated mature hospital management and operating experience in its long -term cultivation, including standardized hospital construction process, professional configuration, diagnosis and treatment, diagnosis and treatment Equipment configuration, etc.

and the unique three -level eye health medical service model are also provided with a ready -made ophthalm chain copy mode for the company, which is conducive to its rapid layout in multi -region in the country, continuously improving the scale effect and brand effect .

has been in the past two decades. Dr. He Wei and his team insisted on the concept of "technology benefiting the people, scientific and technological to the country", and developed He's ophthalmology. Over the years of

, the company has continuously improved the medical service network and expanded the service radius and business scale. Today, the leading market size has been achieved, and it has won the favor of the state -owned assets fund.

Log in to the A stock market will be a new starting point, looking forward to a new surprise that the company brings to investors.

Disclaimer: This report (article) is based on the attributes of the public company of the listed company, the information disclosed by listed companies in accordance with its legal obligations (including but not limited to temporary announcements, regular reports and official interactive platforms, etc.) as the core basis) as core basis, etc. Independent third -party research; market value Fengyun strives to report the content and views of the report (article) objective and fair, but does not guarantee its accuracy, integrity, timeliness, etc.; It constitutes any investment suggestions, and the market value is not responsible for any action taken by using this report.

is content.